PMID- 36222579
OWN - NLM
STAT- MEDLINE
DCOM- 20230208
LR  - 20230216
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 64
IP  - 1
DP  - 2023 Jan
TI  - Incidence of adverse effects in patients receiving ponatinib with concomitant 
      azole antifungals.
PG  - 79-86
LID - 10.1080/10428194.2022.2131409 [doi]
AB  - Ponatinib plus Hyper-CVAD yields a five-year overall survival of 73% in patients 
      with Philadelphia-positive acute lymphoblastic leukemia. Ponatinib dose intensity 
      is associated with increased incidence of adverse effects (AEs), including 
      vascular events. Ponatinib combined with azole antifungals may further increase 
      the risk of AEs due to increased ponatinib exposure. We reviewed 53 patients who 
      received ponatinib with intensive (n = 39; 74%) or low-intensity chemotherapy 
      (n = 14; 26%). Forty-eight patients (91%) received concomitant azole. Ponatinib 
      was commonly initiated at 30 mg (n = 30; 57%) or 45 mg daily (n = 21; 40%). 
      Twenty-six patients (49%) experienced at least one grade >/=3 AE possibly related 
      to ponatinib; 19 (73%) were receiving a ponatinib dose equivalent >/=30mg and 58% 
      >45mg. Eight patients (15%) experienced 10 vascular events, including 1 arterial 
      event; 9 occurred on a ponatinib dose equivalent >/=30mg and 5 occurred while on an 
      azole. Vascular events pose a clinical challenge with the risk potentially 
      increasing with concomitant azoles.
FAU - Marx, Kayleigh R
AU  - Marx KR
AUID- ORCID: 0000-0001-9468-9707
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Rausch, Caitlin R
AU  - Rausch CR
AUID- ORCID: 0000-0002-4166-5717
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Lovell, Alexandra R
AU  - Lovell AR
AUID- ORCID: 0000-0002-0550-3868
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Short, Nicholas J
AU  - Short NJ
AUID- ORCID: 0000-0002-2983-2738
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Paul, Shilpa
AU  - Paul S
AUID- ORCID: 0000-0001-5938-8896
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Jain, Nitin
AU  - Jain N
AUID- ORCID: 0000-0003-0114-8384
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Lee, Jenessa
AU  - Lee J
AUID- ORCID: 0000-0002-8026-9178
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Savoy, J Michael
AU  - Savoy JM
AUID- ORCID: 0000-0002-0945-7264
AD  - Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Ravandi, Farhad
AU  - Ravandi F
AUID- ORCID: 0000-0002-7621-377X
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Jabbour, Elias
AU  - Jabbour E
AUID- ORCID: 0000-0003-4465-6119
AD  - Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221012
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antifungal Agents)
RN  - 4340891KFS (ponatinib)
RN  - 0 (Imidazoles)
RN  - 0 (Pyridazines)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Antifungal Agents/adverse effects
MH  - Incidence
MH  - Philadelphia Chromosome
MH  - Imidazoles/adverse effects
MH  - *Pyridazines/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Protein Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Ponatinib
OT  - ponatinib adverse events
OT  - ponatinib and azoles
EDAT- 2022/10/13 06:00
MHDA- 2023/02/09 06:00
CRDT- 2022/10/12 09:23
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2023/02/09 06:00 [medline]
PHST- 2022/10/12 09:23 [entrez]
AID - 10.1080/10428194.2022.2131409 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2023 Jan;64(1):79-86. doi: 10.1080/10428194.2022.2131409. Epub 
      2022 Oct 12.